SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001104659-24-071756
Filing Date
2024-06-14
Accepted
2024-06-14 16:10:50
Documents
6
Period of Report
2024-08-12

Document Format Files

Seq Description Document Type Size
1 PRE 14A tm2417053-1_pre14a.htm PRE 14A 811515
2 GRAPHIC bc_companytsr-4c.jpg GRAPHIC 52940
3 GRAPHIC bc_netincome-4c.jpg GRAPHIC 50588
4 GRAPHIC lg_outlooktherapeutics-4clr.jpg GRAPHIC 18748
5 GRAPHIC px_24outlookproxy1pg01-bw.jpg GRAPHIC 301630
6 GRAPHIC px_24outlookproxy1pg02-bw.jpg GRAPHIC 268795
  Complete submission text file 0001104659-24-071756.txt   1712055
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: PRE 14A | Act: 34 | File No.: 001-37759 | Film No.: 241044857
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)